OTTAWA, March 28, 2012 /CNW/ - Canada's Research-Based Pharmaceutical Companies (Rx&D) responds to the tabling of Budget 2012 by Ontario Finance Minister Dwight Duncan.
"Rx&D members recognize that healthcare sustainability is central to an economically stable province and to the continued health and well-being of Ontarians," said Russell Williams, President of Canada's Research-Based Pharmaceutical Companies (Rx&D). "The government has signaled a serious commitment to improving Ontario's healthcare system and to a more sustainable healthcare future. Together with world-class intellectual property protection, Ontario can become one the world's leading life science and health outcomes jurisdictions."
Rx&D strongly believes that quality and cost-effective healthcare today hinges on the integration of innovative medicines, patient-centered care, and leading-edge technology. Rx&D members invest over a billion dollars annually to research and develop new medicines and vaccines that help Canadians live healthier and more productive lives while ensuring a more sustainable healthcare system.
"Innovation is central to a better future for our healthcare system. The province must continue to do all that it can to spur the development and uptake of life sciences innovation here in Ontario. The next 25 years are up to all of us," added Mr. Williams.
Specifically in yesterday's budget, Rx&D welcomed the government's focus on home and community care for Ontarians.
"Community-based care puts patients' needs first. It is a policy that not only offers Ontarians the chance to receive high-quality care at home, but also helps the healthcare system by alleviating the strain on limited resources," said Elaine Campbell, President of AstraZeneca Canada Inc. and Chair of Rx&D's Ontario Regional Committee.
Rx&D looks forward to partnering with the Government of Ontario as it works to transform healthcare in the province.
Rx&D is the association of leading research-based pharmaceutical companies dedicated to improving the health of Canadians through the discovery and development of new medicines and vaccines. Our community represents 15,000 men and women working for 50 member companies and invests more than $1 billion in research and development each year to fuel Canada's knowledge-based economy. Guided by our Code of Ethical Practices, our membership is committed to working in partnership with governments, healthcare professionals and stakeholders in a highly ethical manner.
For further information:
E-mail: [email protected]